Phase 2 Trial of S-531011 with RadScopal for Metastatic Colorectal Cancer
This study is testing if the experimental drug S-531011, given by IV, combined with RadScopal™ radiation therapy (HD-XRT), can help people with metastatic colorectal cancer that has been previously treated. You might be able to join if you are at least 18 years old, have a specific type of colorectal cancer (non-MSI-H colorectal adenocarcinoma), and have already received standard chemotherapy. The main goal is to see how safe this combination treatment is and what side effects (adverse events) might occur. The study plans to enroll 30 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 30 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and adverse events will be measured through study completion, which is an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Daniel Haldar, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- safety and adverse events (AEs)Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0